127 related articles for article (PubMed ID: 37399991)
21. Tau Tubulin Kinase 1 (TTBK1), a new player in the fight against neurodegenerative diseases.
Nozal V; Martinez A
Eur J Med Chem; 2019 Jan; 161():39-47. PubMed ID: 30342424
[TBL] [Abstract][Full Text] [Related]
22. ARN25068, a versatile starting point towards triple GSK-3β/FYN/DYRK1A inhibitors to tackle tau-related neurological disorders.
Demuro S; Sauvey C; Tripathi SK; Di Martino RMC; Shi D; Ortega JA; Russo D; Balboni B; Giabbai B; Storici P; Girotto S; Abagyan R; Cavalli A
Eur J Med Chem; 2022 Feb; 229():114054. PubMed ID: 34959172
[TBL] [Abstract][Full Text] [Related]
23. Accelerated neurodegeneration and neuroinflammation in transgenic mice expressing P301L tau mutant and tau-tubulin kinase 1.
Asai H; Ikezu S; Woodbury ME; Yonemoto GM; Cui L; Ikezu T
Am J Pathol; 2014 Mar; 184(3):808-18. PubMed ID: 24418258
[TBL] [Abstract][Full Text] [Related]
24. Novel screening cascade identifies MKK4 as key kinase regulating Tau phosphorylation at Ser422.
Grueninger F; Bohrmann B; Christensen K; Graf M; Roth D; Czech C
Mol Cell Biochem; 2011 Nov; 357(1-2):199-207. PubMed ID: 21638028
[TBL] [Abstract][Full Text] [Related]
25. Pathological phosphorylation of tau and TDP-43 by TTBK1 and TTBK2 drives neurodegeneration.
Taylor LM; McMillan PJ; Liachko NF; Strovas TJ; Ghetti B; Bird TD; Keene CD; Kraemer BC
Mol Neurodegener; 2018 Feb; 13(1):7. PubMed ID: 29409526
[TBL] [Abstract][Full Text] [Related]
26. Ser
Sandhu P; Naeem MM; Lu C; Kumarathasan P; Gomes J; Basak A
Bioorg Med Chem Lett; 2017 Feb; 27(3):642-652. PubMed ID: 27989667
[TBL] [Abstract][Full Text] [Related]
27. Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3β/DYRK1A dual inhibitors for the treatment of Alzheimer's disease.
Liu W; Liu X; Tian L; Gao Y; Liu W; Chen H; Jiang X; Xu Z; Ding H; Zhao Q
Eur J Med Chem; 2021 Oct; 222():113554. PubMed ID: 34098466
[TBL] [Abstract][Full Text] [Related]
28. Virtual screening, pharmacokinetics, molecular dynamics and binding free energy analysis for small natural molecules against cyclin-dependent kinase 5 for Alzheimer's disease.
Shukla R; Singh TR
J Biomol Struct Dyn; 2020 Jan; 38(1):248-262. PubMed ID: 30688165
[TBL] [Abstract][Full Text] [Related]
29. The crystal structure of the catalytic domain of tau tubulin kinase 2 in complex with a small-molecule inhibitor.
Marcotte DJ; Spilker KA; Wen D; Hesson T; Patterson TA; Kumar PR; Chodaparambil JV
Acta Crystallogr F Struct Biol Commun; 2020 Mar; 76(Pt 3):103-108. PubMed ID: 32133995
[TBL] [Abstract][Full Text] [Related]
30. Structure Based Design and Molecular Docking Studies for Phosphorylated Tau Inhibitors in Alzheimer's Disease.
Pradeepkiran JA; Reddy PH
Cells; 2019 Mar; 8(3):. PubMed ID: 30893872
[TBL] [Abstract][Full Text] [Related]
31. Genetic variations in tau-tubulin kinase-1 are linked to Alzheimer's disease in a Spanish case-control cohort.
Vázquez-Higuera JL; Martínez-García A; Sánchez-Juan P; Rodríguez-Rodríguez E; Mateo I; Pozueta A; Frank A; Valdivieso F; Berciano J; Bullido MJ; Combarros O
Neurobiol Aging; 2011 Mar; 32(3):550.e5-9. PubMed ID: 20096481
[TBL] [Abstract][Full Text] [Related]
32. Protective effects of a small molecule inhibitor ligand against hyperphosphorylated tau-induced mitochondrial and synaptic toxicities in Alzheimer disease.
Pradeepkiran JA; Munikumar M; Reddy AP; Reddy PH
Hum Mol Genet; 2021 Dec; 31(2):244-261. PubMed ID: 34432046
[TBL] [Abstract][Full Text] [Related]
33. Identification of abelson tyrosine kinase inhibitors as potential therapeutics for Alzheimer's disease using multiple e-pharmacophore modeling and molecular dynamics.
Palakurti R; Vadrevu R
J Biomol Struct Dyn; 2017 Mar; 35(4):883-896. PubMed ID: 26982633
[TBL] [Abstract][Full Text] [Related]
34. Modulation of tau tubulin kinases (TTBK1 and TTBK2) impacts ciliogenesis.
Bashore FM; Marquez AB; Chaikuad A; Howell S; Dunn AS; Beltran AA; Smith JL; Drewry DH; Beltran AS; Axtman AD
Sci Rep; 2023 Apr; 13(1):6118. PubMed ID: 37059819
[TBL] [Abstract][Full Text] [Related]
35. Tau-tubulin kinase 1 enhances prefibrillar tau aggregation and motor neuron degeneration in P301L FTDP-17 tau-mutant mice.
Xu J; Sato S; Okuyama S; Swan RJ; Jacobsen MT; Strunk E; Ikezu T
FASEB J; 2010 Aug; 24(8):2904-15. PubMed ID: 20354135
[TBL] [Abstract][Full Text] [Related]
36. An identification of MARK inhibitors using high throughput MALDI-TOF mass spectrometry.
Hruba L; Polishchuk P; Das V; Hajduch M; Dzubak P
Biomed Pharmacother; 2022 Feb; 146():112549. PubMed ID: 34923338
[TBL] [Abstract][Full Text] [Related]
37. Tau-tubulin kinase 1 phosphorylates TDP-43 at disease-relevant sites and exacerbates TDP-43 pathology.
Tian Y; Wang Y; Jablonski AM; Hu Y; Sugam JA; Koglin M; Stachel SJ; Zhou H; Uslaner JM; Parmentier-Batteur S
Neurobiol Dis; 2021 Dec; 161():105548. PubMed ID: 34752923
[TBL] [Abstract][Full Text] [Related]
38. Structure-Based Virtual Screening and De Novo Design to Identify Submicromolar Inhibitors of G2019S Mutant of Leucine-Rich Repeat Kinase 2.
Park H; Kim T; Kim K; Jang A; Hong S
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361616
[TBL] [Abstract][Full Text] [Related]
39. Identification of novel scaffold of benzothiazepinones as non-ATP competitive glycogen synthase kinase-3β inhibitors through virtual screening.
Zhang P; Hu HR; Huang ZH; Lei JY; Chu Y; Ye DY
Bioorg Med Chem Lett; 2012 Dec; 22(23):7232-6. PubMed ID: 23099099
[TBL] [Abstract][Full Text] [Related]
40. Molecular hydrogen attenuates sepsis-induced cognitive dysfunction through regulation of tau phosphorylation.
Qi B; Song Y; Chen C; Zhao L; Ma W; Meng S; Zhuang X; Lin H; Liang J; Cui Y; Xie K
Int Immunopharmacol; 2023 Jan; 114():109603. PubMed ID: 36538853
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
